ROIV
Roivant Sciences Ltd. · Healthcare
CEO Matthew Gline sold $33K of Roivant Sciences Ltd.
Sold$32,675
$3.84Price
8,509Shares
−1%Stake
What ROIV did after the filing
- The stock from Thu, Apr 28 open, $3.75
- +3.2%
- S&P 500, same days
- −7.7%
Measured over 30 trading days, to the Jun 10 close.
Traded Mon, Apr 25. Filed Wed, Apr 27, 7:00 PM ET, after the close. Returns use the Apr 28 open and the Jun 10 close. Not investment advice.